Actinogen: Presentation, CEO Sessions Brisbane

Company Presentations

by Carolyn Herbert

Actinogen Limited (ASX:ACW) CEO Dr Bill Ketelbey told the conference ‘Alzheimer’s disease is emerging as one of the most significant health challenges of our time. A person develops Alzheimer’s disease almost every minute in the US.’
 
Dr Ketelbey outlined the development and milestones of the company’s lead drug Xanamem, most recently the completion of a second Phase I trial.
 
The biotechnology company is now preparing for a Phase II trial. The trial will be a double blind, randomised, placebo controlled study to assess the safety, tolerability and efficacy of Xanamem in participants with mild Alzheimer's disease.

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?